Skip to main content
OpenTrials
Completed

NCT Number: NCT00402623

The Effect of Quercetin in Sarcoidosis

The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.

Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Maastricht University

Maastricht, 6200 MD, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis
  • no smoking
  • no treatment

Exclusion criteria

  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung
  • use of food supplements or vitamins

Treatment and study plan

Quercetin

Dietary Supplement

1000 mg quercetin within 24 hours

Placebo

Other

Primary outcomes

  1. antioxidant status after 24 hours

    Time frame: 24 hours

  2. inflammatory status after 24 hours

    Time frame: 24 hours

Secondary outcomes

  1. plasma quercetin concentration after 24 hours

    Time frame: 24 hours

  2. plasma malondialdehyde (MDA) levels after 24 hours

    Time frame: 24 hours

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

Registry information

Official study title

The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis

Important dates

Study start
2006
Primary completion
2006
Study completion
2006
First posted
Nov 22, 2006
Registry last updated
Feb 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.